• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by PLx Pharma Inc. (Amendment)

    2/14/23 1:38:55 PM ET
    $PLXP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PLXP alert in real time by email
    SC 13G/A 1 d406333dsc13ga.htm SC 13G/A SC 13G/A

    CUSIP No. 72942A107

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

    (Amendment No.1)*

     

     

    PLX PHARMA INC.

    (Name of Issuer)

    Common Stock, $.001 par value per share

    (Title of Class of Securities)

    72942A107

    (CUSIP Number)

    December 31, 2022

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☒ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes)

     

     

     


    CUSIP No. 72942A107

     

      1    

      NAMES OF REPORTING PERSONS

     

      MSD Partners, L.P.

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

      (a)  ☐        (b)  ☒

     

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5    

      SOLE VOTING POWER

     

      -0-

       6  

      SHARED VOTING POWER

     

      686,685 (1)

       7  

      SOLE DISPOSITIVE POWER

     

      -0-

       8  

      SHARED DISPOSITIVE POWER

     

      686,685 (1)

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      686,685 (1)

    10  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

      ☐

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

      2.4% (2)

    12  

      TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

      PN

     

    (1)

    Represents shares of common stock underlying the 2,129 shares of Series B Convertible Preferred Stock beneficially owned by the Reporting Persons.

    (2)

    The percentage used herein and in the rest of this Schedule 13G is calculated based upon 29,137,692 shares as of November 8, 2022 of the Issuer’s common stock outstanding as reported in the Issuer’s Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission (“SEC”) on November 10, 2022, and assuming conversion of all of the 2,129 shares of Series B Convertible Preferred Stock beneficially owned by the Reporting Persons.


    CUSIP No. 72942A107

     

      1    

      NAMES OF REPORTING PERSONS

     

      MSD Credit Opportunity Master Fund, L.P.

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

      (a)  ☐        (b)  ☒

     

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Cayman Islands

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5    

      SOLE VOTING POWER

     

      -0-

       6  

      SHARED VOTING POWER

     

      686,685 (1)

       7  

      SOLE DISPOSITIVE POWER

     

      -0-

       8  

      SHARED DISPOSITIVE POWER

     

      686,685 (1)

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      686,685 (1)

    10  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

      ☐

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

      2.4% (2)

    12  

      TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

      PN

     

    (1)

    Represents shares of common stock underlying the 2,129 shares of Series B Convertible Preferred Stock beneficially owned by the Reporting Persons.

    (2)

    The percentage used herein and in the rest of this Schedule 13G is calculated based upon 29,137,692 shares as of November 8, 2022 of the Issuer’s common stock outstanding as reported in the Issuer’s Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission (“SEC”) on November 10, 2022, and assuming conversion of all of the 2,129 shares of Series B Convertible Preferred Stock beneficially owned by the Reporting Persons.


    CUSIP No. 72942A107

     

    Item 1(a)

    Name of Issuer:

    The name of the issuer is PLx Pharma Inc. (the “Company”).

     

    Item 1(b)

    Address of Issuer’s Principal Executive Offices:

    The Company’s principal executive office is located at 9 Fishers Lane, Suite E, Sparta, New Jersey, 07871.

     

    Item 2(a)

    Name of Person Filing:

    This Schedule 13G is being jointly filed by and on behalf of each of MSD Partners, L.P. (“MSD Partners”) and MSD Credit Opportunity Master Fund, L.P. (“MSD Credit Opportunity Master Fund”). MSD Credit Opportunity Master Fund is the direct owner of the securities covered by this statement.

    MSD Partners is the investment manager of, and may be deemed to beneficially own securities beneficially owned by, MSD Credit Opportunity Master Fund. MSD Partners (GP), LLC (“MSD GP”) is the general partner of, and may be deemed to beneficially own securities beneficially owned by, MSD Partners. Gregg R. Lemkau maintains investment discretion over this investment and therefore may be deemed to beneficially own securities beneficially owned by MSD GP.

    The Reporting Persons have entered into a Joint Filing Agreement, dated February 14, 2023, a copy of which is filed with this Schedule 13G as Exhibit 99.1, pursuant to which the Reporting Persons have agreed to file this statement jointly in accordance with the provisions of Rule 13d-1(k)(1) under the Act.

    Neither the filing of this statement nor anything herein shall be construed as an admission that any person other than the Reporting Persons is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, the beneficial owner of any securities covered by this statement.

     

    Item 2(b)

    Address of Principal Business Office or, if none, Residence:

    The address of the principal business office of MSD Partners is One Vanderbilt Avenue, 26th Floor, New York, New York 10017.

    The address of the principal business office of MSD Credit Opportunity Master Fund is One Vanderbilt Avenue, 26th Floor, New York, New York 10017.

     

    Item 2(c)

    Citizenship:

    MSD Partners is organized as a limited partnership under the laws of the State of Delaware.

    MSD Credit Opportunity Master Fund is a limited partnership organized under the laws of the Cayman Islands.

     

    Item 2(d)

    Title of Class of Securities:

    Common Stock, par value $0.001 per share.

     

    Item 2(e)

    CUSIP No.:

    72942A107

     

    Item 3

    If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

    Not applicable.


    CUSIP No. 72942A107

     

    Item 4

    Ownership:

     

      A.

    MSD Partners, L.P.

     

      (a)

    Amount beneficially owned: 686,685

     

      (b)

    Percent of class: 2.4%

     

      (c)

    Number of shares as to which such person has:

     

      (i)

    Sole power to vote or direct the vote: -0-

     

      (ii)

    Shared power to vote or direct the vote: 686,685

     

      (iii)

    Sole power to dispose or direct the disposition: -0-

     

      (iv)

    Shared power to dispose or direct the disposition: 686,685

     

      B.

    MSD Credit Opportunity Master Fund, L.P.

     

      (a)

    Amount beneficially owned: 686,685

     

      (b)

    Percent of class: 2.4%

     

      (c)

    Number of shares as to which such person has:

     

      (i)

    Sole power to vote or direct the vote: -0-

     

      (ii)

    Shared power to vote or direct the vote: 686,685

     

      (iii)

    Sole power to dispose or direct the disposition: 0

     

      (iv)

    Shared power to dispose or direct the disposition: 686,685

     

      C.

    MSD Partners (GP), LLC

     

      (a)

    Amount beneficially owned: 686,685

     

      (b)

    Percent of class: 2.4%

     

      (c)

    Number of shares as to which such person has:

     

      (i)

    Sole power to vote or direct the vote: -0-

     

      (ii)

    Shared power to vote or direct the vote: 686,685


    CUSIP No. 72942A107

     

      (iii)

    Sole power to dispose or direct the disposition: -0-

     

      (iv)

    Shared power to dispose or direct the disposition: 686,685

     

      D.

    Gregg R. Lemkau

     

      (a)

    Amount beneficially owned: 686,685

     

      (b)

    Percent of class: 2.4%

     

      (c)

    Number of shares as to which such person has:

     

      (i)

    Sole power to vote or direct the vote: -0-

     

      (ii)

    Shared power to vote or direct the vote: 686,685

     

      (iii)

    Sole power to dispose or direct the disposition: -0-

     

      (iv)

    Shared power to dispose or direct the disposition: 686,685

     

    Item 5

    Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof each of the Reporting Persons has ceased to be the beneficial owner of more than five percent of the class of securities, check the following  ☒.

     

    Item 6

    Ownership of More Than Five Percent on Behalf of Another Person:

    Not applicable.

     

    Item 7

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person:

    Not applicable.

     

    Item 8

    Identification and Classification of Members of the Group:

    Not applicable.

     

    Item 9

    Notice of Dissolution of Group:

    Not applicable.

     

    Item 10

    Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.


    CUSIP No. 72942A107

     

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this Schedule 13G is true, complete and correct.

     

    Date: February 14, 2023
    MSD Partners, L.P.
    By:   MSD Partners (GP), LLC
    Its:   General Partner
    By:   /s/ Robert K. Simonds
      Robert K. Simonds, Authorized Signatory
    MSD Credit Opportunity Master Fund, L.P.
    By:   MSD Partners, L.P.
    Its:   Investment Adviser
    By:   MSD Partners (GP), LLC
    Its:   General Partner
    /s/ Robert K. Simonds
    Robert K. Simonds, Authorized Signatory


    CUSIP No. 72942A107

     

    EXHIBIT INDEX

     

    Exhibit   

    Description of Exhibit

    Exhibit 99.1    Joint Filing Agreement dated February 14, 2023.
    Get the next $PLXP alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PLXP

    DatePrice TargetRatingAnalyst
    12/7/2021$14.00Market Perform → Outperform
    Raymond James
    9/21/2021$29.00Buy
    BWS Financial
    More analyst ratings

    $PLXP
    SEC Filings

    See more
    • SEC Form 15-12G filed by PLx Pharma Inc.

      15-12G - PLx Pharma Winddown Corp. (0001497504) (Filer)

      10/18/23 4:01:55 PM ET
      $PLXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PLx Pharma Inc. filed SEC Form 8-K: Bankruptcy or Receivership, Other Events, Financial Statements and Exhibits

      8-K - PLx Pharma Winddown Corp. (0001497504) (Filer)

      9/20/23 4:39:55 PM ET
      $PLXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PLx Pharma Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - PLx Pharma Winddown Corp. (0001497504) (Filer)

      8/22/23 5:24:50 PM ET
      $PLXP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PLXP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Giordano Natasha bought $14,977 worth of shares (4,100 units at $3.65), increasing direct ownership by 378% to 5,186 units

      4 - PLx Pharma Inc. (0001497504) (Issuer)

      3/16/22 8:35:24 AM ET
      $PLXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: O'Connor Rita M bought $50,122 worth of shares (13,700 units at $3.66), increasing direct ownership by 106% to 26,670 units

      4 - PLx Pharma Inc. (0001497504) (Issuer)

      3/16/22 8:33:47 AM ET
      $PLXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Valentino Michael J

      4 - PLx Pharma Inc. (0001497504) (Issuer)

      2/24/22 8:18:05 PM ET
      $PLXP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PLXP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • PLx Pharma upgraded by Raymond James with a new price target

      Raymond James upgraded PLx Pharma from Market Perform to Outperform and set a new price target of $14.00

      12/7/21 5:38:25 AM ET
      $PLXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BWS Financial initiated coverage on PLx Pharma with a new price target

      BWS Financial initiated coverage of PLx Pharma with a rating of Buy and set a new price target of $29.00

      9/21/21 8:29:27 AM ET
      $PLXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oppenheimer initiated coverage on PLx Pharma with a new price target

      Oppenheimer initiated coverage of PLx Pharma with a rating of Outperform and set a new price target of $20.00

      4/9/21 7:21:28 AM ET
      $PLXP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PLXP
    Financials

    Live finance-specific insights

    See more

    $PLXP
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $PLXP
    Leadership Updates

    Live Leadership Updates

    See more
    • PLx Pharma Inc. Reports Third Quarter 2022 Results and Provides Business Update

      - Significant Reduction in Operating Expenses - Strategic Alternatives Process Ongoing Total Net Sales of $0.4 Million, Including $0.3 Million of Unfavorable Adjustments for Additional Trade Allowances and Incremental Sales Returns Reserves in Q3 2022Total Operating Expenses Significantly Lower by $2.8 Million, or 22%, in Q3 2022 vs. Q3 2021; $4.4 Million or 31% Lower Sequentially vs. Q2 2022GAAP Net Loss of ($0.30) Per Diluted Share in Q3 2022; Adjusted Non-GAAP Net Loss Per Diluted Share of ($0.37)Cash & Cash Equivalent Balance of $25.8 Million as of September 30, 2022 SPARTA, N.J., Nov. 10, 2022 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ:PLXP) ("PLx" or the "Company"), is a c

      11/10/22 5:00:00 PM ET
      $PLXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PLx Pharma Inc. to Report Third Quarter 2022 Financial Results on November 11, 2022, and Provide Business Update

      SPARTA, N.J., Oct. 26, 2022 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ:PLXP) ("PLx" or the "Company") is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ that has the potential to improve the absorption of many drugs currently on the market and to reduce the risk of stomach injury associated with certain drugs. The Company, with its lead products VAZALORE 81 mg and VAZALORE 325 mg liquid-filled aspirin capsules (referred to together as "VAZALORE®"), today announced that it will release its third quarter 2022 financial results before the open of the U.S. financial markets on Friday, November 11, 2022. Followi

      10/26/22 9:00:00 AM ET
      $PLXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PLx Pharma Inc. Reports Second Quarter 2022 Results and Provides Business Update

      - Initiates Evaluation of Strategic Alternatives to Enhance Stockholder Value - Reports Positive Results of VAZALORE® 81 mg Patient Experience Survey - Streamlines Sales & Marketing Plan Total Net Sales of $0.5 Million, Including $0.4 Million of Unfavorable Adjustments for Additional Trade Allowances and Incremental Sales Returns Reserves in Second Quarter of 2022Total Operating Expenses Were Lower by $4.9 Million in Second Quarter of 2022 vs. Q1 2022GAAP Net Loss of ($0.43) Per Diluted Share in Second Quarter of 2022; Adjusted Non-GAAP Net Loss Per Diluted Share of ($0.52)Cash & Cash Equivalent Balance of $35.7 Million as of June 30, 2022 SPARTA, N.J., Aug. 12, 2022 (GLOBE NEWSWIRE) -

      8/12/22 6:50:00 AM ET
      $PLXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PLx Pharma Inc. Enters into a Stalking Horse Asset Purchase Agreement to Sell VAZALORE® and Substantially All of its Assets

      SPARTA, N.J., April 12, 2023 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ:PLXP) ("PLx" or the "Company"), is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ and VAZALORE®, an FDA-approved liquid-filled aspirin capsule, available in 81 mg and 325 mg doses. The Company today announced that it entered into a stalking horse asset purchase agreement (the "APA") with PLx Acquisition Company, LLC, a wholly-owned subsidiary of Greenwood Brands, LLC ("Buyer"), to acquire substantially all of the Company's assets (the "Sale"). The Company intends to file voluntary petitions for relief under Chapter 11 of Title 11 of the

      4/12/23 5:24:09 PM ET
      $PLXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PLx Pharma Inc. Receives Nasdaq Delisting Notice

      SPARTA, N.J., April 11, 2023 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ:PLXP) ("PLx" or the "Company"), is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ that has the potential to improve the absorption of many drugs currently on the market and to reduce the risk of stomach injury associated with certain drugs. The Company had previously announced that on October 3, 2022, it was notified by the Listing Qualifications Department (the "Listing Qualifications Department") of the Nasdaq Stock Market LLC ("Nasdaq") that the Listing Qualifications Department has determined to delist the Company's securities from Na

      4/11/23 4:28:31 PM ET
      $PLXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PLx Pharma Inc. Reports Third Quarter 2022 Results and Provides Business Update

      - Significant Reduction in Operating Expenses - Strategic Alternatives Process Ongoing Total Net Sales of $0.4 Million, Including $0.3 Million of Unfavorable Adjustments for Additional Trade Allowances and Incremental Sales Returns Reserves in Q3 2022Total Operating Expenses Significantly Lower by $2.8 Million, or 22%, in Q3 2022 vs. Q3 2021; $4.4 Million or 31% Lower Sequentially vs. Q2 2022GAAP Net Loss of ($0.30) Per Diluted Share in Q3 2022; Adjusted Non-GAAP Net Loss Per Diluted Share of ($0.37)Cash & Cash Equivalent Balance of $25.8 Million as of September 30, 2022 SPARTA, N.J., Nov. 10, 2022 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ:PLXP) ("PLx" or the "Company"), is a c

      11/10/22 5:00:00 PM ET
      $PLXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PLx Pharma Inc. Appoints Janet Barth to Newly Created Role of Vice President, Investor Relations & Corporate Communications

      SPARTA, N.J., Jan. 19, 2022 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ:PLXP) ("PLx" or the "Company"), is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ that has the potential to improve the absorption of many drugs currently on the market and to reduce the risk of stomach injury associated with certain drugs. The Company, with its lead products VAZALORE™ 325 mg and VAZALORE™ 81 mg liquid-filled aspirin capsules (referred to together as "VAZALORE"), announced today the appointment of Janet M. Barth as Vice President, Investor Relations & Corporate Communications, effective immediately. As a member of the Exec

      1/19/22 6:50:00 AM ET
      $PLXP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PLXP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by PLx Pharma Inc.

      SC 13G - PLx Pharma Inc. (0001497504) (Subject)

      4/6/23 9:15:24 AM ET
      $PLXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by PLx Pharma Inc. (Amendment)

      SC 13G/A - PLx Pharma Inc. (0001497504) (Subject)

      2/14/23 1:38:55 PM ET
      $PLXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by PLx Pharma Inc. (Amendment)

      SC 13G/A - PLx Pharma Inc. (0001497504) (Subject)

      2/16/22 6:15:38 AM ET
      $PLXP
      Biotechnology: Pharmaceutical Preparations
      Health Care